Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Indivior-Cannabis

More Like This

PR Newswire associated0

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

PR Newswire associated0

Indivior Announces Q2 2024 Financial Results

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

PR Newswire associated0

Indivior Announces Q3 2024 Financial Results

PR Newswire associated0

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025